Stock Scan November 2017: Generics get volatile
Executive Summary
Generic drug producers endured very mixed fortunes on the world's stock markets, with firms ending November at opposite ends of Scrip's Stock Scan monthly league table.
You may also be interested in...
As Regeneron Worries Rise On Eylea Combo Failure, Eyes Turn To PANORAMA
Failure of RUBY and ONYX combo trials with Eylea and nesvacumab fan concerns over longer-term growth prospects for Regeneron's ophthalmic franchise.
First ‘Digital Medicine’ Approved, Slow Rollout Planned
FDA has approved Abilify MyCite, a treatment for some psychiatric conditions that integrates a drug with a sensor that records when the medication is taken. The goal is to track medication compliance. It is an important regulatory milestone for the nascent field of digital medicine, but many questions about the market remain.
Payer Pushback Underpins Mallinckrodt's Disappointing Q3 Results
Mallinckrodt's high-priced H.P Acthar Gel was under pressure in the third quarter, which management attributed to payer complexities. The issue is broader than just Acthar, firm says.